{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:24Z","timestamp":1786997904787,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIAID Division of Intramural Research","award":["NIAID Division of Clinical Research"],"award-info":[{"award-number":["NIAID Division of Clinical Research"]}]},{"name":"Battelle Memorial Institute's prime contract","award":["HHSN272200700016I"],"award-info":[{"award-number":["HHSN272200700016I"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.virusres.2014.11.028","type":"journal-article","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T21:48:13Z","timestamp":1417643293000},"page":"54-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine"],"prefix":"10.1016","volume":"197","author":[{"given":"Amy B.","family":"Papaneri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Bernbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jahrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed F.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2014.11.028_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virusres.2014.11.028_bib0010","doi-asserted-by":"crossref","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virusres.2014.11.028_bib0015","doi-asserted-by":"crossref","first-page":"10605","DOI":"10.1128\/JVI.00558-11","article-title":"Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses","volume":"85","author":"Blaney","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0042-6822(90)90433-R","article-title":"Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19","volume":"175","author":"Conzelmann","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2014.11.028_bib0025","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1099\/0022-1317-81-9-2147","article-title":"Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo study","volume":"81","author":"Etessami","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0030","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1099\/vir.0.80844-0","article-title":"A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies","volume":"86","author":"Faber","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0035","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","article-title":"Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response","volume":"76","author":"Faber","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0040","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.01870-09","article-title":"Characterization of a single-cycle rabies virus-based vaccine vector","volume":"84","author":"Gomme","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0045","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2014.11.028_bib0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2005.09.018","article-title":"Filovirus assembly and budding","volume":"344","author":"Hartlieb","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2014.11.028_bib0055","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/v4020258","article-title":"Filovirus entry: a novelty in the viral fusion world","volume":"4","author":"Hunt","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.virusres.2014.11.028_bib0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/bsp.2011.0051","article-title":"Evaluation of perceived threat differences posed by filovirus variants","volume":"9","author":"Kuhn","year":"2011","journal-title":"Biosecurity Bioterrorism: Biodefense Strategy, Pract., Sci."},{"key":"10.1016\/j.virusres.2014.11.028_bib0065","first-page":"1","volume":"57","author":"Manning","year":"2008"},{"key":"10.1016\/j.virusres.2014.11.028_bib0070","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2014.11.028_bib0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.virol.2006.04.038","article-title":"Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization","volume":"352","author":"Marzi","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2014.11.028_bib0080","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1586\/erv.10.105","article-title":"Experimental rabies vaccines for humans","volume":"9","author":"McGettigan","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virusres.2014.11.028_bib0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0090","doi-asserted-by":"crossref","first-page":"13455","DOI":"10.1128\/JVI.78.24.13455-13459.2004","article-title":"Immunogenicity study of glycoprotein-deficient rabies virus expressing simian\/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque","volume":"78","author":"McKenna","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0095","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0092-8674(00)81072-7","article-title":"Budding of rabies virus particles in the absence of the spike glycoprotein","volume":"84","author":"Mebatsion","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.virusres.2014.11.028_bib0100","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1073\/pnas.93.14.7310","article-title":"Highly stable expression of a foreign gene from rabies virus vectors","volume":"93","author":"Mebatsion","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2014.11.028_bib0105","doi-asserted-by":"crossref","first-page":"e1001121","DOI":"10.1371\/journal.ppat.1001121","article-title":"Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner","volume":"6","author":"Nanbo","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virusres.2014.11.028_bib0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.virol.2012.07.020","article-title":"A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence","volume":"434","author":"Papaneri","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2014.11.028_bib0115","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JVI.02327-07","article-title":"The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread","volume":"82","author":"Pulmanausahakul","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4161\/hv.6.6.11097","article-title":"Recent advances in Ebolavirus vaccine development","volume":"6","author":"Richardson","year":"2010","journal-title":"Hum. Vaccines"},{"key":"10.1016\/j.virusres.2014.11.028_bib0125","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/emboj\/17.5.1289","article-title":"Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus","volume":"17","author":"Schnell","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.virusres.2014.11.028_bib0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2260","article-title":"The cell biology of rabies virus: using stealth to reach the brain","volume":"8","author":"Schnell","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0135","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.virusres.2014.11.028_bib0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2006.05.010","article-title":"Rabies virus glycoprotein as a carrier for anthrax protective antigen","volume":"353","author":"Smith","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2014.11.028_bib0145","first-page":"300","article-title":"Membrane binding and bending in Ebola VP40 assembly and egress","volume":"5","author":"Stahelin","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fmicb.2012.00034","article-title":"Filovirus tropism: cellular molecules for viral entry","volume":"3","author":"Takada","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virusres.2014.11.028_bib0155","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1073\/pnas.83.11.3914","article-title":"Walking along the rabies genome: is the large G-L intergenic region a remnant gene?","volume":"83","author":"Tordo","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170214005036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170214005036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T23:51:12Z","timestamp":1566085872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170214005036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":31,"alternative-id":["S0168170214005036"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2014.11.028","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2014.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}